Years of translational research have successfully improved treatment outcomes for common dermatological conditions such as ...
Every year, 10 million people contract tuberculosis (TB), a disease caused by the bacterium Mycobacterium tuberculosis (Mtb), and approximately 1.5 million patients succumb to the disease. Treatment ...
Around 1.5 million patients succumb to the disease caused by the bacterium Mycobacterium tuberculosis (Mtb). The novel ...
Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...
Ensoma Inc.’s lead program, EN-374, has been granted orphan drug and rare pediatric disease designations by the FDA for the ...
Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo treatments capable of precisely and durably engineering the hematopoietic system, today announced the U.S ...
Results of a retrospective case study revealed that the incidence of cutaneous pyogenic granuloma varies by age, sex, and anatomical location.
Government of India has provided tax relief on life-saving drugs and medicines used for rare diseases. As per the Ministry of Finance’s response in Rajya Sabha on February 11, 2025, basic customs duty ...
The lowest inter-rater ICC was observed for the identification of granulomas 0.56 (0.43 to 0.67). The intent of these analyses was to assess the criterion validity of scores against a global measure ...
Granulomas and Sarcoidosis One way the body tries to protect ... When they do occur, they cause lesions and are often associated with inflammatory bowel disease or other chronic conditions. Pyoderma ...
and correlate these factors with patient phenotype (predominantly granulomatous or vasculitic lesions), duration, extent and severity of disease, and differences in concurrent therapies.
As the authors discuss, at least some of the highlighted exposures have been linked to granulomatous disease in adults, giving biological plausibility to their findings. However, there does appear to ...